Unicycive Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders’ Equity (Details)

Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended
	Jul. 11, 2023	Jul. 31, 2021	Jun. 30, 2026	Mar. 31, 2025	Jun. 30, 2026	Apr. 06, 2026	Dec. 31, 2025	Aug. 26, 2025	Jun. 30, 2025	Jun. 11, 2025	Feb. 18, 2025	Dec. 19, 2024	Dec. 18, 2024	Dec. 11, 2024	Oct. 31, 2024	Oct. 09, 2024	Aug. 14, 2024	Jul. 29, 2024	Jul. 25, 2024	Jul. 23, 2024	Jul. 05, 2024	Jun. 25, 2024	Mar. 26, 2024
Stockholders’ Equity Deficit [Line Items]
Common stock, shares authorized			400,000,000		400,000,000		400,000,000
Common stock, par value (in Dollars per share)			$ 0.001		$ 0.001		$ 0.001
Common stock share issued			27,855,257		27,855,257		22,114,245
Common stock price (in Dollars per share)			$ 1,000		$ 1,000
Common Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued						462,245		652,900			140,000					550,000	350,200	135,900	375,600	355,000		595,600
Shares of common stock			462,245	140,000
Conversion of the shares series preferred stock	1,951,621
IPO [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued		500,000
Common stock price (in Dollars per share)		$ 50
Convertible debt shares granted					18,419
IPO [Member] \| Warrant [Member]
Stockholders’ Equity Deficit [Line Items]
Shares warrants		400,000
Common stock price (in Dollars per share)		$ 0.1
Warrants term		5 years	5 years		5 years
Exercise price per warrant (in Dollars per share)		$ 60	$ 60		$ 60
Purchase of additional warrants		60,000
Proceeds of warrants (in Dollars)		$ 7,500
IPO [Member] \| Common Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock price (in Dollars per share)		$ 49.9
Shares of common stock					73,691
Series A-2 Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Conversion of the shares series preferred stock	43,649
Series A-2 Preferred Stock [Member] \| Common Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued														462,455									285,000
Series A-2 Preferred Stock [Member] \| Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Shares of common stock	43,649
Conversion of the shares series preferred stock														2,266.03									1,396.5
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued																					4,211,800
Series B-2 Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued										300,000		300,300	144,100		43,800
Conversion of the shares series preferred stock										3,000		3,003	1,441		438						7,882
Series A-2 Prime Preferred Stock [Member] \| Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Conversion of the shares series preferred stock						2,265		3,199.21			686					2,695	1,715.98	665.91	1,840.44	1,739.5		2,918.44
Series A-3 Warrants and Received [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued									277,000
Conversion of the shares series preferred stock									1,500,000